They are of particular interest in BLBC, because abnormal activity in the PI3K/Akt/mTOR signaling axis has been described both in preclinical models and in clinical cohorts in this breast cancer subtype [8,15-17]. The gene discussed is MTOR; the disease is breast cancer.